$ALLR News

Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

Allarity Therapeutics Highlights DRP Technology, Patent And Lab Advances To Support Stenoparib Development And Partnerships

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

Allarity Therapeutics Expands Capabilities Of Its In-House Medical Laboratory To Include Proteomics And Cell Line Research

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Allarity Therapeutics Secures CLIA For In-House Lab

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic

Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

Allarity Therapeutics To Present A Trial-In-Progress Poster At The ESMO Gynaecological Cancers Congress, June 17–19

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?